CTAD 2024 | A Phase II trial of nilotinib in patients with dementia with Lewy bodies

Charbel Moussa, MBBS, PhD, Georgetown University Medical Center, Washington, DC, speaks about a Phase II trial of nilotinib in patients with dementia with Lewy bodies. The study found that those treated with 200 milligrams of nilotinib showed significant improvements in cognitive function, as measured by the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 14 (ADAS-Cog14), and a 70% reduction in falls. The study’s biomarker results also indicated a beneficial effect of nilotinib. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.